New Pharmaceutical Industry Investment in Szigetszentmiklós
2026. 03. 06.
Danish-based Xellia Pharmaceuticals is investing €70.85 million in Szigetszentmiklós, further strengthening Hungary's role in the European healthcare and antibiotic supply chain. The development aims to create a modern, automated pharmaceutical manufacturing plant and will create 91 new high value-added jobs.
Headquartered in Copenhagen, Xellia Pharmaceuticals is a specialty pharmaceutical company focused on producing anti-infective medicines and providing critical care therapies. It operates three state-of-the-art manufacturing facilities in Denmark, Hungary and China, as well as R&D centers in Norway.
The €70.85 million investment will establish a high-tech, automated pharmaceutical manufacturing plant where the company will produce products based on antibiotic active ingredients classified as critical by the European Union and the WHO. Production will take place using specialized drying and packaging technologies.
As part of the development, warehouse capacity, utility systems and modern office infrastructure will also be built to support modern, high-precision manufacturing processes.
The company is a market leader in anti-infective medicines and serves around 500 pharmaceutical partners worldwide.
Sector articles
Hungarian-owned Biolab Zrt. is strengthening Pest County through a capacity expansion investment.
2026. 02. 25.
Life Sciences #Life SciencesFrench-owned Hungarian pharmaceutical company Egis Gyógyszergyár Zrt. is set to implement another large-scale investment to boost efficiency and capacity at its base in Körmend.
2025. 07. 28.
Life Sciences #Life SciencesSwiss-owned Novartis expands its Hungarian presence by adding a regional R&D center. Apart from its core research functions, the facility will play a crucial role in coordinating related activities in several countries.
2023. 05. 05.
Life Sciences #Life Sciences